Amino derivatives of EM-138 and methods of treating angiogenesis with same
US6420414B1 · kind B1 · utility
86Cited by
25References
52Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 9, 2000 |
| Grant date | Jul 16, 2002 |
| Priority date | — |
| Expiry date | Nov 9, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.